Log In
BCIQ
Print this Print this
 

Kallikrein inhibitor

  Manage Alerts
Collapse Summary General Information
Company Global Blood Therapeutics Inc.
DescriptionKallikrein inhibitor
Molecular Target Kallikrein
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationAngioedema
Indication DetailsTreat hereditary angioedema (HAE)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today